Skip to main content
Digital Recording

The Evolving Science of the Use of Psychedelic Substances in the Treatment of PTSD

Average Rating:
Not yet rated
Michael Mithoefer, MD
1 Hour 30 Minutes
May 28, 2021
Product Code:
Media Type:
Digital Recording
Never expires.


As psychiatry struggles to develop new, more effective treatments, clinical trials combining psychotherapy and the drug MDMA, also known as Ecstasy, are producing stunning results. New research suggests that incorporating psychedelics like MDMA and psilocybin into talk therapy can dramatically boost outcomes with an array of issues, including PTSD, anxiety, depression, relationship blocks, even drug addiction. If ongoing trials continue with favourable results, FDA approval for certified therapists to use MDMA- and psilocybin-assisted therapy in their practices could be on the horizon. Guided in this workshop by the psychiatrist at the helm of the MDMA-assisted psychotherapy trials, you’ll explore:

  • The rationale for using drugs like MDMA, psilocybin and other psychedelics as catalysts for psychotherapy
  • The MDMA-assisted psychotherapy process, illustrated with video clips
  • How these inner-directed approaches to therapy respect and support clients' innate healing intelligence
  • New opportunities for psychotherapists to receive training in this approach



This online program is worth 1.5 hours CPD.



Michael Mithoefer, MD's Profile

Michael Mithoefer, MD Related seminars and products

Michael Mithoefer, MD, clinical assistant professor of psychiatry at the Medical University of South Carolina. In 2009, he completed & published the first FDA approved clinical trial of MDMA assisted psychotherapy for treatment-resistant PTSD, followed by completion of a Phase II trial. He is overseeing a multisite Phase III study of MDMA-assisted psychotherapy in 13 sites around the US (including the Trauma Research Foundation), and another MDMA-assisted psychotherapy multisite study in Europe and Israel.


Speaker Disclosures:
Financial: Dr. Michael Mithoefer has employment relationships with Columbia University, Bassett Healthcare Network, Medical University of South Carolina, and MAPS Public Benefit Corporation. He has an ownership interest in Awakn Life Sciences and serves on the scientific advisory board. Dr. Mithoefer receives a speaking honorarium and recording royalties from PESI, Inc.
Non-financial: Dr. Michael Mithoefer is a fellow of the American Psychiatric Association.


  1. Evaluate the results of clinical trials of MDMA-assisted psychotherapy for PTSD and their treatment implications.
  2. Determine the clinical uses of MDMA-assisted psychotherapy in the treatment of trauma.
  3. Appraise the role therapists play in the sessions while the client is under the effects of these drugs, and how to facilitate the talk-therapy sessions that precede and follow it to improve client outcomes.
  4. Assess the risks and limitations of MDMA and psilocybin-assisted psychotherapy.


  • History of MDMA and Psilocybin
  • Physiological effects and side effects, risk/benefit profile
  • Design of past and ongoing non-profit-sponsored clinical trials of MDMA-assisted psychotherapy
  • Results of Six Completed MDMA Phase 2 Clinical trials
  • Design of ongoing Phase 3 Trials of MDMA-assisted psychotherapy
  • Overview of psilocybin clinical trials
  • Status of FDA drug development – MDMA and Psilocybin, including Breakthrough Therapy Designation
  • The manualized therapeutic method used in clinical trials of MDMA-assisted psychotherapy
    • Essential elements of “inner directed” approach
    • Illustrated elements of “inner directed” approach
    • Challenges that may arise
  • Therapist training program for MDMA-assisted psychotherapy

Target Audience

  • Counselors
  • Social Workers
  • Psychologists
  • Psychotherapists
  • Therapists
  • Marriage & Family Therapists
  • Addiction Counselors
  • Case Managers
  • Physicians
  • Nurses
  • Other Mental Health Professionals


Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to or call 01235847393.

Please wait ...

Back to Top